Barbara Leutgeb
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Immunotherapy and Immune Responses, Glioma Diagnosis and Treatment, Brain Metastases and Treatment
Most-Cited Works
- → G12-G13–LARG–mediated signaling in vascular smooth muscle is required for salt-induced hypertension(2007)675 cited
- → Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial(2016)195 cited
- → Integrin α2β1 Is Required for Regulation of Murine Wound Angiogenesis but Is Dispensable for Reepithelialization(2006)124 cited
- → CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials(2024)44 cited
- → Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.(2013)29 cited
- → Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma(2017)20 cited
- → Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study(2014)16 cited
- → Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.(2013)14 cited
- → Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.(2014)13 cited
- → O10.04 * THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE(2014)13 cited